MH

Mark Haberlin

Abacus Group | Non-Executive Director, Non-Executive Chairman
Mr Haberlin has over 25 years of audit, risk management, capital transactions and mergers and acquisitions experience across industries including healthcare, real estate and financial services. Mark is the Lead Independent Director and Chair of the Audit and Risk Committee of Abacus Property Group. Previously, Mark was an independent Non-Executive Director and the Chair of the Audit and Risk Committee of Laybuy Group Holdings Limited, the Chair of PwC Australia and PwC's Public Reporting Panel, as well as a Director of the European Australia Business Council and PwC Asia Pacific. He is chair of Risk Committee.

Companies and Roles

Company
Title
Tenure
Since
ABG
Abacus Group
  • Non-Executive Director
  • Non-Executive Chairman
7yrs, 8mthNov 2018
ACL
Australian Clinical Labs Limited
  • Non-Executive Director
5yrs, 2mthApr 2021

Holdings

Company
Last Notice
Direct Shares
Indirect Shares
Options
Convertibles
ABG
Abacus Group
30/06/25N/A42,292N/AN/A
ACL
Australian Clinical Labs Limited
30/06/25N/A47,500N/AN/A

Transactions

Company
Date
Type
Amount
Price
Value
Notes
ACL
Australian Clinical Labs Limited
22/11/21
Buy
22,500$4.399$98,988On-market trade